Zobrazeno 1 - 10
of 71
pro vyhledávání: '"S P, Ivy"'
Autor:
Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, S. Percy Ivy, Lisa Wang, Lee-Anne Stayner, Lillian L. Siu, Anna Spreafico
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-15 (2022)
Abstract Background Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK) profile of trametini
Externí odkaz:
https://doaj.org/article/dfe80954e86a42808631f0fc9dd65391
Autor:
Oluwadamilola Olaku, Barbara A. Conley, S. Percy Ivy, Lisa M. McShane, Louis M. Staudt, Sophie M. King, Megan Sansevere, Benjamin Kim, Jeffrey D. White
Publikováno v:
Translational Oncology, Vol 25, Iss , Pp 101484- (2022)
Introduction: The Exceptional Responders Initiative (ERI) at the National Cancer Institute attempts to correlate unusually good outcomes in patients with cancer with genetic targets in tumors and the therapies the patients received. It is not known i
Externí odkaz:
https://doaj.org/article/88a2f3c40f2742269a89ec944cd51d28
Autor:
Ovidiu C. Andronesi, Morteza Esmaeili, Ronald J. H. Borra, Kyrre Emblem, Elizabeth R. Gerstner, Marco C. Pinho, Scott R. Plotkin, Andrew S. Chi, April F. Eichler, Jorg Dietrich, S. Percy Ivy, Patrick Y. Wen, Dan G. Duda, Rakesh Jain, Bruce R. Rosen, Gregory A. Sorensen, Tracy T. Batchelor
Publikováno v:
npj Precision Oncology, Vol 1, Iss 1, Pp 1-9 (2017)
Metabolic imaging reveals anti-angiogenic (AA) therapy mechanisms in glioblastoma (GBM) GBM is the most common and aggressive type of malignant primary brain tumors (glioma). Patients with GBM have less than 5% survival at 5 years with the best exist
Externí odkaz:
https://doaj.org/article/cff8891abc634b19b196fe665c1e1ac0
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Uterine cervix or vaginal cancers have inherent overactivity of ribonucleotide reductase (RNR), making these cancers rational targets for therapy based on interruption of cisplatin-radiotherapy-induced DNA damage repair. We conducted a pilot, open-la
Externí odkaz:
https://doaj.org/article/751c5d6582154f6080b4693151e82a43
Autor:
Channing J. Paller, Erich P. Huang, Thomas Luechtefeld, Holly A. Massett, Christopher C. Williams, Jinxiu Zhao, Amy E. Gravell, Tami Tamashiro, Steven A. Reeves, Gary L. Rosner, Michael A. Carducci, Lawrence Rubinstein, S. Percy Ivy
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Experimental therapeutic oncology agents are often combined to circumvent tumor resistance to individual agents. However, most combination trials fail to demonstrate sufficient safety and efficacy to advance to a later phase. This study collected sur
Externí odkaz:
https://doaj.org/article/cd7815f522cd4ad1b572ff59f04dc918
Autor:
Charles A. Kunos, S. Percy Ivy
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Clinical ribonucleotide reductase (RNR) inhibitors have reinvigorated enthusiasm for radiochemotherapy treatment of patients with regionally advanced stage cervical cancers. About two-thirds of patients outlive their cervical cancer (1), even though
Externí odkaz:
https://doaj.org/article/8f2f95d88d5b4ef691c1e59acbc31624
Autor:
S. Percy Ivy, Elise C. Kohn
Publikováno v:
Frontiers in Oncology, Vol 6 (2016)
Understanding the biology of cancer at the cellular and molecular levels, and the application of such knowledge to the patient, has opened new opportunities and uncovered new obstacles to quality cancer care delivery. Benefits include our ability to
Externí odkaz:
https://doaj.org/article/f7dd810edc7d49e79542d342c588778b
Autor:
S. P. Ivy, William T. Barry, Jean A. Hurteau, Gini F. Fleming, Christin Whalen, Michael J. Birrer, Sreenivasa Nattam, Elise C. Kohn, Ronald J. Buckanovich, Jennifer Curtis, J.-M. Lee, Bobbie J. Rimel, Mary K. Buss, Ursula A. Matulonis, Weixiu Luo, Joyce F. Liu
Publikováno v:
Annals of Oncology. 30:551-557
BACKGROUND: Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic. In the primary analysis of this phase II study, combination cediranib/olaparib improved progression-free survival (PFS) compared with olaparib a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57c439da50f3b1b8854d7b38d56d29c3
https://doi.org/10.1093/annonc/mdz018
https://doi.org/10.1093/annonc/mdz018
Autor:
Joshua F. Zeidner, Judith E. Karp, Amanda L. Blackford, B. Douglas Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Jacqueline M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt
Publikováno v:
Haematologica, Vol 99, Iss 4 (2014)
Myeloproliferative neoplasms are a varied group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform into a secondary acute myeloid leukemia that is ultimately fatal. Triapine is a novel inhibitor of the M2
Externí odkaz:
https://doaj.org/article/7729b37966d04d358e59f3c89c4653be
Autor:
Scott H. Kaufmann, Judith E. Karp, Mark R. Litzow, Ruben A. Mesa, William Hogan, David P. Steensma, Karen S. Flatten, David A. Loegering, Paula A. Schneider, Kevin L. Peterson, Matthew J. Maurer, B. Douglas Smith, Jacqueline Greer, Yuhong Chen, Joel M. Reid, S. Percy Ivy, Matthew M. Ames, Alex A. Adjei, Charles Erlichman, Larry M. Karnitz
Publikováno v:
Haematologica, Vol 96, Iss 11 (2011)
Background In preclinical studies the heat shock protein 90 (Hsp90) inhibitor tanespimycin induced down-regulation of checkpoint kinase 1 (Chk1) and other client proteins as well as increased sensitivity of acute leukemia cells to cytarabine. We repo
Externí odkaz:
https://doaj.org/article/f7f7717a6c364771a1cbefbdd5f290b1